Overview

Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
A Double-blind Study of the Pharmacokinetic Properties of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects with Type 1 Diabetes
Phase:
Phase 1
Details
Lead Sponsor:
Biodel
Treatments:
Insulin
Insulin Lispro
Insulin, Globin Zinc